Christof Mauch
German historian
Christof Mauch's AcademicInfluence.com Rankings
Download Badge
History
Why Is Christof Mauch Influential?
(Suggest an Edit or Addition)According to Wikipedia, Christof Mauch is a German historian, presently director of the Rachel Carson Center for Environment and Society in Munich, Germany, and since 2007 professor of American Cultural History and Transatlantic Relations at Ludwig Maximilian University of Munich. From 1999 to 2007 Christof Mauch was the director of the German Historical Institute in Washington D.C.. Mauch received his Dr. phil. in Modern German Literature from the University of Tübingen in 1990, and his Dr. phil. in Modern History in 1998 from the University of Cologne. He has published and edited many books in the fields of U.S. and German History and Environmental History. From 2009 to 2011 Christof Mauch was chair of the Board of Directors of the International Consortium of Environmental History Organizations and from 2011 to 2013 President of the European Society for Environmental History. In May 2013 he was appointed Honorary Professor at Renmin University, Beijing, China.In the same year he was awarded the Carl-von-Carlowitz Prize of Germany's Council for Sustainable Development, and in 2017 he received the Award for a Distinguished Career in Public Environmental History from the American Society for Environmental History.
Christof Mauch's Published Works
Published Works
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial (2012) (2647)
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. (2021) (162)
- Health-related Quality of Life, Fatigue, and Depression Under Low-Dose IFN-&agr; Therapy in Melanoma Patients (2014) (8)
- Integrated, cross-sectoral psycho-oncology (isPO): a new form of care for newly diagnosed cancer patients in Germany (2022) (7)
- Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting Subgroups (2022) (6)
- Risk Factors for Relapse after Intentional Discontinuation of Immune Checkpoint Inhibitors in Melanoma Patients (2021) (3)
- Real‐world outcomes using PD‐1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland (2022) (3)
- Radiomics for the non-invasive prediction of the BRAF mutation status in patients with melanoma brain metastases. (2021) (2)
- Complete excision of squamous cell carcinoma is superior to salvage radiotherapy for microscopic residual disease (2022) (2)
- Treatment‐specific evaluation of the modified Glasgow‐Prognostic‐Score in patients with advanced cutaneous melanoma (2021) (2)
- Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma (2015) (1)
- 546 Results from Phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM) (2021) (1)
- P14.06 Radiomics for the non-invasive determination of the BRAF mutational status in patients with melanoma brain metastases (2021) (0)
- [Brain metastases-Interdisciplinary approach towards a personalized treatment]. (2021) (0)
- Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM). (2022) (0)
- C-Reactive Protein and Lymphocyte-to-Monocyte Ratio Predict Recurrence in Stage III Melanoma Patients with Microscopic Sentinel Lymph Node Metastasis (2023) (0)
- [76-year-old female with a painless gluteal tumor : Preparation for the specialist examination: part 31]. (2019) (0)
- Oligometastatic disease and visceral resections in advanced malignant melanoma: a propensity-matched analysis (2023) (0)
- NIMG-04. PREDICTING THE BRAF MUTATIONAL STATUS IN PATIENTS WITH MELANOMA BRAIN METASTASES USING RADIOMICS - A BICENTRIC STUDY (2021) (0)
- [Melanoma microenvironment-impact of modern therapies]. (2022) (0)
- SARCOPENIA AS BIOMARKER FOR IMMUNOTHERAPY OUTCOMES AND IMMUNE-RELATED ADVERSE EVENTS – A SYSTEMATIC REVIEW AND META-ANALYSIS microenvironment and microbiome in Immunotherapy (2021) (0)
- PO-0891: Application of radiation therapy to brain metastases with parallel or non-parallel PD-1 inhibition (2020) (0)
- Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group. (2020) (0)
- Outcomes after retreatment with MAPK inhibitors and immune checkpoint inhibitors in melanoma patients. (2021) (0)
- 821P Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma (2022) (0)
- Tenascin C is a valuable marker for melanoma progression independent of mutational status and MAPK inhibitor therapy (2022) (0)
- Phase II trial Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial (2018) (0)
- The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients (2020) (0)
This paper list is powered by the following services:
Other Resources About Christof Mauch
What Schools Are Affiliated With Christof Mauch?
Christof Mauch is affiliated with the following schools: